A study of an experimental drug to prevent HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a cisgender woman (assigned female at birth)
- You must be HIV-negative (tested negative for HIV-1 and HIV-2)
- You have had vaginal sex with a male partner at least twice in the last 3 months
- You weigh at least 35 kg (about 77 pounds)
- You have not used certain long-acting HIV prevention drugs (like cabotegravir or lenacapavir) ever
- You have not received an HIV vaccine or HIV antibodies in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (MK-8527) combined with a common antibiotic (rifampin) in people with untreated latent TB. It aims to see if the combination is safe and how the body processes it.
This study tests an experimental medicine (alimatravir, also called MK-8527) as a way to prevent HIV infection. The trial is designed specifically for transgender and gender diverse people who are on gender-affirming hormone therapy and have a low risk of HIV exposure.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.